Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now
We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are ...
Regeneron finalists from Long Island in Washington, D.C., for a shot at up to $250,000 in prize money
Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...
Business Wire1d
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm ...
REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc.
A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...
GlobalData on MSN12d
Regeneron makes second bid for blood cancer therapy approval
The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Regeneron announces FDA accepted for review BLA for odronextamab
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for review the resubmission of the ...
Managed Healthcare Executive4d
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...
BioSpace12d
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...